SCHEMBL6179732

SCHEMBL6179732

O=CCCCC(Cl)c1ccc(F)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.33
CYP19A1 P11511 1/20 0.31
HIF1A Q16665 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HDAC9 Q9UKV0 1/20 0.31
HDAC5 Q9UQL6 1/20 0.31
SCN5A Q14524 1/20 0.31
CYP17A1 P05093 1/20 0.31
IDO1 P14902 1/20 0.31
TDO2 P48775 1/20 0.31
TBXA2R P21731 2/20 0.30
GABBR2 O75899 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26109029 0.93 IDO1 (0.32) SLC6A3CYP19A1HDAC3HDAC4HDAC1
SCHEMBL6223969 0.93 IDO1 (0.32) SLC6A3CYP19A1HDAC3HDAC4HDAC1
SCHEMBL6223713 0.84 TSHR (0.38) HIF1AGABBR2GABBR1
SCHEMBL66024 0.81 SCN5A (0.44) SLC6A3CYP19A1SCN5ATBXA2R
SCHEMBL6222100 0.81 CES2 (0.36) CYP19A1
SCHEMBL6221702 0.80 HDAC4 (0.37) CYP19A1HDAC4HDAC7HDAC5IDO1
SCHEMBL12860041 0.79 HIF1A (0.31) SLC6A3HIF1AHDAC3HDAC4HDAC1
SCHEMBL6221926 0.77 IDO1 (0.34) SLC6A3HDAC3HDAC4HDAC1HDAC7
SCHEMBL26127277 0.77 IDO1 (0.34) SLC6A3HDAC3HDAC4HDAC1HDAC7
SCHEMBL6224374 0.77 ALDH1A1 (0.41) CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406631-A4 DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON UNIV MICHIGAN (US) 2005-03-23 EP disclosed
EP-1411942-A4 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMA CORP (US) 2005-01-26 EP disclosed
EP-1411942-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS Synaptic Pharmaceutical Corporation (US) 2004-04-28 EP disclosed
EP-1406631-A2 DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2004-04-14 EP disclosed
WO-2003004027-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2003-01-16 WO disclosed
WO-2002100350-A2 DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON THE REGENTS OF UNIVERSITY OF MICHIGAN (US) 2002-12-19 WO disclosed